89 master-"https:" "https:" "https:" "https:" "UCL" "UCL" research jobs at Northeastern University
Sort by
Refine Your Search
-
, vision, dental, paid time off, tuition assistance, wellness & life, retirement- as well as commuting & transportation. Visit https://hr.northeastern.edu/benefits/ for more information. All qualified
-
functional supervision over supporting research staff. Primary responsibility is ensuring that the research is complete. The appointment generally does not extend beyond two years. Major Responsibilities
-
well as commuting & transportation. Visit https://hr.northeastern.edu/benefits/ for more information. All qualified applicants are encouraged to apply and will receive consideration for employment without regard
-
benefits package for benefit eligible employees. This includes medical, vision, dental, paid time off, tuition assistance, wellness & life, retirement- as well as commuting & transportation. Visit https
-
employees. This includes medical, vision, dental, paid time off, tuition assistance, wellness & life, retirement- as well as commuting & transportation. Visit https://hr.northeastern.edu/benefits/ for more
-
are reviewed regularly and are subject to change. To apply, visit https://northeastern.wd1.myworkdayjobs.com/en-US/careers/job/Boston-MA-Main-Campus/Alnylam-Pharmaceuticals-Clinical-Science-Postdoctoral-Research
-
eligible employees. This includes medical, vision, dental, paid time off, tuition assistance, wellness & life, retirement- as well as commuting & transportation. Visit https://hr.northeastern.edu/benefits
-
assistance, wellness & life, retirement- as well as commuting & transportation. Visit https://hr.northeastern.edu/benefits/ for more information. All qualified applicants are encouraged to apply and will
-
are reviewed regularly and are subject to change. To apply, visit https://northeastern.wd1.myworkdayjobs.com/en-US/careers/job/Boston-MA-Main-Campus/Ironwood-Pharmaceuticals-Regulatory-Affairs-Postdoctoral
-
, acquired, life-threatening blood disorder, and an approved therapy for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), two rare and serious kidney